Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 6, 2005, Pages 1583-1586

  MacDougall, James M ^a   Zhang, Xiao Dong ^a   Polgar, Willma E ^b   Khroyan, Taline V ^b   Toll, Lawrence ^b   Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

^b SRI INTERNATIONAL   (United States)

Author keywords

Morphine; Morphine 6 glucuronide; Pain

Indexed keywords

AMINE; BENZYL DERIVATIVE; CARBOHYDRATE DERIVATIVE; CARBON; DELTA OPIATE RECEPTOR AGONIST; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); GUANOSINE TRIPHOSPHATE; KAPPA OPIATE RECEPTOR AGONIST; MORPHINE; MORPHINE 6 GLUCURONIDE DERIVATIVE; MORPHINE DERIVATIVE; MU OPIATE RECEPTOR AGONIST; NITROGEN; PARTIAL AGONIST; PROPANE; SILANE; SILANE DERIVATIVE; SULFUR 35; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMICAL BOND; CONTROLLED STUDY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MOLECULAR STABILITY; NONHUMAN; PH; RADIOASSAY; RAT;

EID: 14644402967     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.01.072     Document Type: Article

References (18)

1. R. Osborne, P. Thompson, S. Joel, D. Trew, N. Patel, and M. Slevin Br. J. Clin. Pharmacol. 34 1992 130 138
2. R. Osborne, S. Joel, D. Trew, and M. Slevin Lancet i 1988 828
3. P.A. Carrupt, B. Testa, A. Bechalany, N. el Tayar, P. Descas, and D. Perrissoud J. Med. Chem. 34 1991 272 1275
4. Gutman, A. L.; Nisnevitch, G.; Yudovitch, L.; Rokhman, I. U.S. Patent 6,737,518, 2004 and references cited therein
5. R.T. Penson, S.P. Joel, M. Roberts, A. Gloyne, S. Beckwith, and M.L. Slevin Br. J. Clin. Pharmacol. 53 2002 347 354
6. M.H.D. Postema, and J.L. Piper Org. Lett. 5 2003 1721 1723
7. M.J. Kiefel, R.T. Thomson, M. Radocanovi, and M. von Itzstein J. Carbohydr. Chem. 18 1999 937 959
8. J.M. MacDougall, X.-D. Zhang, W.E. Polgar, T.V. Khroyan, L. Toll, and J.R. Cashman J. Med. Chem. 47 2004 5809 5815
9. H. Kuzuhara, and H.G. Fletcher J. Org. Chem. 32 1967 2531 2534
10. M.W. Rathke J. Am. Chem. Soc. 92 1970 3222 3223
11. M.D. Lewis, J.K. Cha, and Y. Kishi J. Am. Chem. Soc. 104 1982 4976 4978
12. R. Tiedemann, P. Turnbull, and H.W. Moore J. Org. Chem. 64 1999 4030 4041
13. J.M. MacDougall, X.-D. Zhang, W.E. Polgar, T.V. Khroyan, L. Toll, and J.R. Cashman Bioorg. Med. Chem. 12 2004 5983 5990
14. B.P. Czech, and R.A. Bartsch J. Org. Chem. 49 1984 4076 4078
15. 3CN/MeOH (0.7 mL). The organic solvent was removed under a stream of argon. To the residue MeOH (0.2 mL) was added and the resulting material was analyzed by HPLC using the reverse phase conditions described above. The extraction efficiency was 45%. Selected metabolic extracts were also analyzed with an M-8000 ion trap mass spectrometer (Hitachi, San Jose, CA) equipped with an electrospray ionization source. Sample delivery was carried out in the flow injection analysis mode using a LaChrom separation module with an isocratic solvent system of MeOH/water/HCOOH (50:50:0.17, v/v) running at0.2 mL/min
16. N. Zaveri, W. Polgar, C. Olsen, A.B. Kelson, P. Grundt, J.W. Lewis, and L. Toll Eur. J. Pharmacol. 428 2001 29 36
17. A.V. Stachulski, F. Scheinmann, J.R. Ferguson, J.L. Law, K.W. Lumbard, P. Hopkins, N. Patel, S. Clarke, A. Gloyne, and S.P. Joel Bioorg. Med. Chem. Lett. 13 2003 1207 1214
18. J.R. Traynor, and S.R. Nahorski Mol. Pharmacol. 47 1995 848 854